Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L31 pseudogene 53 (RPL31P53) is a processed pseudogene corresponding to the ribosomal protein L31 gene. Pseudogenes are genomic sequences similar to known genes but are generally considered non-functional due to disruptive mutations or lack of transcription/translation. RPL31P53 is not believed to encode a functional protein and has no reported biological or disease relevance. It is not considered a therapeutic target or a receptor, nor does it have established use as a biomarker or drug target. It exists as one of numerous processed pseudogenes in the human genome derived from the RPL31 gene, which encodes a structural component of the ribosomal 60S subunit; however, the pseudogene itself lacks coding activity or characterized function. Key clarifications: - RPL31P53 refers specifically to a pseudogene, not a protein-coding gene. - There are no functional studies or therapeutic implications reported for RPL31P53. - Data about ribosomal protein L31 (RPL31) do not apply to the pseudogene RPL31P53. - Any mention of biological or disease roles for ribosomal pseudogenes includes general information rather than something specific for RPL31P53
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L31 pseudogene 53 (RPL31P53).